Clinical trial
Phase II Clinical Trial of Intra-lesional Administration of TG1042 (Adenovirus-Interferon-gamma) in Patients With Relapsing Primary Cutaneous B-Cell Lymphomas.
NCT00394693 is registered in ClinicalTrials.gov with Transgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Clinical Trial of Intra-lesional Administration of TG1042 (Adenovirus-Interferon-gamma) in Patients With Relapsing Primary Cutaneous B-Cell Lymphomas.
- Lead sponsor
- Transgene
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- April 30, 2010
- Enrollment
- 13 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.